ThromboGenics, a company specializing in biotherapeutics for vascular diseases, cancer, and eye diseases, has announced the start of a Phase II trial of microplasmin to treat age-related wet macular degeneration (AMD).
Author: Global Cancer Consortium
Cytori Therapeutics is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.
Vertex Pharmaceuticals has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C.
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
Patients with psoriasis demonstrated 79% improvement in the Psoriasis Scoring Index after four weeks of daily treatment with PH-10.
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.